EMA Authorised: Caprelsa (vandetanib) — Sanofi B.V.

View source ↗

Summary

The European Medicines Agency authorised Caprelsa (vandetanib) for thyroid neoplasms, including medullary thyroid carcinoma, with Sanofi B.V. as the marketing a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medullary Thyroid Carcinoma
• Thyroid Neoplasms

Drugs mentioned

• Caprelsa (vandetanib)

Snippet

Status: Authorised. Therapeutic area: Thyroid Neoplasms. MAH: Sanofi B.V.. Decision date: 13/11/2025